The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

Vanderbilt's Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.

A machine learning algorithm identified areas of skin affected by chronic graft-versus-host disease on par with clinicians, opening the door to streamlining and standardizing this measure of patient response to therapy.

The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.

Vanderbilt research shows that 10-second videos of white blood cell motion in the skin’s microvasculature greatly improved the prediction of which stem cell and bone marrow transplant patients would have a relapse of their blood cancer.

Adolescent and young adult oncology patients and caregivers experience psychosocial impairment and financial toxicity at the time of cancer diagnosis, findings that will inform interventions to support patient and caregiver well-being.

Jordan Berlin, MD, has been appointed interim leader of Vanderbilt's Division of Hematology and Oncology in the Department of Medicine.